stockrow
Monday 9 November 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMPCAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024.
- Revenue
- +138.9%
- EPS
- +32.7%
- Free cash flow
- +20.4%
Quarter to September 2026, against a year earlier
4.06
0.34
+9.14%
Follow CAMP
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (146.12%) | (545.85%) | (209.28%) | (145.07%) |
+8 more TTM periods Free account |
|
| (109.89%) | (148.23%) | (102.60%) | (82.00%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(112.47%) | (147.45%) | (98.63%) | (79.67%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.33) | (0.50) | (0.45) | (0.55) | |
Free Cash Flow |
(26.37) | (28.68) | (26.25) | (29.80) | |
Capital Expenditures |
(0.83) | (0.09) | — | (0.24) | |
| Other line items | |||||
Cash ROIC |
(11.35%) | (33.19%) | (20.06%) | (18.79%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
766.32% | 917.69% | 971.43% | 1,092.11% | |
Selling, General and Administrative Expense of Revenue |
334.74% | 424.81% | 451.19% | 496.20% | |
Share Based Compensation of Revenue |
123.65% | 131.36% | 117.16% | 114.29% | |
Operating CF/Net income |
0.21 | 0.27 | 0.30 | 0.37 | |
Depreciation/Fixed assets |
0.00 | 0.99 | 0.90 | 0.70 | |
Capex/Depreciation |
(0.43) | (0.05) | 0.00 | (0.15) | |
Revenue per Share |
0.07 | 0.07 | 0.07 | 0.06 | |
Operating CF per Share |
(0.32) | (0.49) | (0.45) | (0.55) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.16 | 0.02 | 0.00 | 0.07 |
Columns are period end dates · fundamentals updated 5 Nov 2026